DK2892535T3 - Fremgangsmåde til adjuverende cancerbehandling - Google Patents
Fremgangsmåde til adjuverende cancerbehandling Download PDFInfo
- Publication number
- DK2892535T3 DK2892535T3 DK13835019.4T DK13835019T DK2892535T3 DK 2892535 T3 DK2892535 T3 DK 2892535T3 DK 13835019 T DK13835019 T DK 13835019T DK 2892535 T3 DK2892535 T3 DK 2892535T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedure
- cancer treatment
- adjuvant cancer
- adjuvant
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696375P | 2012-09-04 | 2012-09-04 | |
| PCT/US2013/057432 WO2014039375A1 (en) | 2012-09-04 | 2013-08-30 | Method of adjuvant cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2892535T3 true DK2892535T3 (da) | 2022-01-03 |
Family
ID=50237545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13835019.4T DK2892535T3 (da) | 2012-09-04 | 2013-08-30 | Fremgangsmåde til adjuverende cancerbehandling |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US20150216868A1 (enExample) |
| EP (2) | EP2892535B1 (enExample) |
| JP (3) | JP2015527374A (enExample) |
| KR (1) | KR102134585B1 (enExample) |
| CN (2) | CN104582706A (enExample) |
| AU (2) | AU2013313050A1 (enExample) |
| BR (1) | BR112015004578A2 (enExample) |
| CA (1) | CA2882437C (enExample) |
| CY (1) | CY1124812T1 (enExample) |
| DK (1) | DK2892535T3 (enExample) |
| ES (1) | ES2900825T3 (enExample) |
| HR (1) | HRP20211817T1 (enExample) |
| HU (1) | HUE056646T2 (enExample) |
| IN (1) | IN2015KN00449A (enExample) |
| LT (1) | LT2892535T (enExample) |
| PL (1) | PL2892535T3 (enExample) |
| PT (1) | PT2892535T (enExample) |
| RU (1) | RU2640180C2 (enExample) |
| SI (1) | SI2892535T1 (enExample) |
| WO (1) | WO2014039375A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104582706A (zh) | 2012-09-04 | 2015-04-29 | 葛兰素史克有限责任公司 | 辅助癌症治疗的方法 |
| CN111534580B (zh) | 2013-12-28 | 2024-06-04 | 夸登特健康公司 | 用于检测遗传变异的方法和系统 |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| WO2018203219A1 (en) * | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| US11890286B2 (en) * | 2018-04-17 | 2024-02-06 | The University Of Chicago | Methods and compositions for treating cancer |
| CN109106893B (zh) * | 2018-11-12 | 2021-04-20 | 上海市中西医结合医院 | 一种调节肠道屏障功能的中药复方制剂及其制备方法 |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| CN114981298B (zh) * | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| US20250032494A1 (en) | 2021-12-06 | 2025-01-30 | My Personal Therapeutics Ltd | A combination treatment for cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100883289B1 (ko) * | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물 |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| HUE060206T2 (hu) * | 2009-10-16 | 2023-02-28 | Novartis Ag | MEK gátlót és B-Raf gátlót tartalmazó kombináció |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| CN104582706A (zh) | 2012-09-04 | 2015-04-29 | 葛兰素史克有限责任公司 | 辅助癌症治疗的方法 |
-
2013
- 2013-08-30 CN CN201380046144.4A patent/CN104582706A/zh active Pending
- 2013-08-30 IN IN449KON2015 patent/IN2015KN00449A/en unknown
- 2013-08-30 DK DK13835019.4T patent/DK2892535T3/da active
- 2013-08-30 LT LTEPPCT/US2013/057432T patent/LT2892535T/lt unknown
- 2013-08-30 BR BR112015004578A patent/BR112015004578A2/pt not_active IP Right Cessation
- 2013-08-30 EP EP13835019.4A patent/EP2892535B1/en active Active
- 2013-08-30 RU RU2015105821A patent/RU2640180C2/ru active
- 2013-08-30 CA CA2882437A patent/CA2882437C/en active Active
- 2013-08-30 EP EP21190550.0A patent/EP3981408A1/en active Pending
- 2013-08-30 HU HUE13835019A patent/HUE056646T2/hu unknown
- 2013-08-30 ES ES13835019T patent/ES2900825T3/es active Active
- 2013-08-30 AU AU2013313050A patent/AU2013313050A1/en not_active Abandoned
- 2013-08-30 PL PL13835019T patent/PL2892535T3/pl unknown
- 2013-08-30 HR HRP20211817TT patent/HRP20211817T1/hr unknown
- 2013-08-30 PT PT138350194T patent/PT2892535T/pt unknown
- 2013-08-30 SI SI201331951T patent/SI2892535T1/sl unknown
- 2013-08-30 KR KR1020157008387A patent/KR102134585B1/ko active Active
- 2013-08-30 WO PCT/US2013/057432 patent/WO2014039375A1/en not_active Ceased
- 2013-08-30 JP JP2015530072A patent/JP2015527374A/ja active Pending
- 2013-08-30 CN CN201710300645.0A patent/CN107308164A/zh active Pending
- 2013-08-30 US US14/422,182 patent/US20150216868A1/en not_active Abandoned
-
2016
- 2016-10-13 AU AU2016244279A patent/AU2016244279B2/en active Active
-
2017
- 2017-04-05 US US15/479,663 patent/US20170202842A1/en not_active Abandoned
- 2017-11-10 JP JP2017216933A patent/JP6511117B2/ja active Active
-
2018
- 2018-08-07 US US16/056,702 patent/US20180338979A1/en not_active Abandoned
-
2019
- 2019-04-05 JP JP2019072361A patent/JP6684941B2/ja active Active
- 2019-10-28 US US16/664,978 patent/US10869869B2/en active Active
-
2020
- 2020-11-11 US US17/095,200 patent/US20210060021A1/en not_active Abandoned
-
2021
- 2021-12-15 CY CY20211101105T patent/CY1124812T1/el unknown
-
2022
- 2022-12-07 US US18/062,764 patent/US20230330091A1/en not_active Abandoned
-
2025
- 2025-04-14 US US19/178,730 patent/US20260207608A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289300A (en) | Combination therapy for treating cancer | |
| DK2897620T3 (da) | Fremgangsmåde til behandling af cancer | |
| BR112014032105A2 (pt) | método para o tratamento de câncer | |
| LT2707030T (lt) | Vėžio gydymas | |
| BR112014007603A2 (pt) | métodos de tratamento do câncer | |
| HUE057061T2 (hu) | Kombinációs terápia rák kezelésére | |
| HUE046790T2 (hu) | A rák kezelésének módszerei | |
| HUE046667T2 (hu) | Rák kombinatív kezelése | |
| HUE047198T2 (hu) | Fitokannabinoidok emlõrák kezelésére | |
| BR112014012880A2 (pt) | tratamento imunogênico do câncer | |
| HUE045314T2 (hu) | Kombinációs terápia rák kezelésére | |
| BR112014031806A2 (pt) | método para tratamento de câncer positivo para gd2 | |
| PL2739153T3 (pl) | Leczenie raka sutka | |
| IL238249B (en) | Cancer treatment | |
| DK2849760T3 (da) | Fremgangsmåder til oligonukleotid-chelatkompleks | |
| LT2914254T (lt) | Kombinacinės terapijos chemoresistencinių vėžių gydymui | |
| HRP20180670T1 (hr) | Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka | |
| DK3290035T3 (da) | Procaspase-kombinationsterapi til behandling af cancer | |
| DK2825558T3 (da) | Kombinationsterapi til behandling af ovariecancer | |
| SMT201600235B (it) | Predittori per il trattamento del cancro | |
| SI2892535T1 (sl) | Postopek adjuvantnega zdravljenja raka | |
| DK2802351T3 (da) | Midler til behandling af triple-negativ brystkræft | |
| EP2789306A4 (en) | TREATMENT SYSTEM | |
| SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
| DK2872176T3 (en) | Cancer treatment |